INTRODUCTION

Historical Perspectives
Endovascular treatment of intracranial aneurysms was first described in the early 1970s in the pioneering paper of Serbinenko. He treated aneurysms with detachable balloons that were positioned in the parent artery or in the aneurysm lumen itself through a microcatheter (1,2). In 1991, Guglielmi et al. (3, 4) described the endovascular occlusion of intracranial aneurysms using electrolytic detachable platinum coils (Target Therapeutics/Boston Scientific). The Guglielmi detachable coils (GDCs) could be introduced through a microcatheter into the aneurysm lumen and detached from a stainless steel microwire by an electrical current. In 1995 the device was approved by the Food and Drug Administration (FDA) and has become widely used in patients with ruptured and unruptured intracranial aneurysms. The GDC technology has evolved ever since, and as clinical experience with this technique has accumulated, it has become the method of choice for the endovascular treatment of intracranial aneurysms. Improved microcatheter and microwire designs have greatly facilitated intracranial intravascular navigation, allowing catheterization of distal aneurysms. Until recently, endovascular treatment in the Unites States was reserved for aneurysms not amenable to surgical clipping. In August 2003, the FDA granted approval to market GDC for the treatment of all brain aneurysms. Continuous technical advances and increasing clinical experience with endovascular techniques as well as its minimal invasiveness have made endovascular treatment an attractive alternative, even in patients who could be treated by conventional neurosurgical clipping.
COMPARISON OF ENDOVASCULAR COILING WITH NEUROSURGICAL CLIPPING
Endovascular aneurysm treatment strategies are now challenging neurosurgical clipping as the standard approach to treatment of cerebral aneurysms. In some institutions, GDC coiling is even considered the first-line treatment in these patients (5-7). It was estimated that in August 2002, 100,000 patients with intracranial aneurysms had been treated with GDCs worldwide (8). Considering these large and increasing numbers, a comparison of the efficacy and risk of morbidity and mortality of the two treatment strategies must be made. Comparisons between surgical and endovascular series should be made with caution because of the heterogeneity in study design, patients, and aneurysms (9).
A small randomized single-institution trial compared the outcomes of surgical clipping and endovascular treatment in 109 patients with ruptured intracranial aneurysms. The basic characteristics of the patients in both treatment groups were similar in terms of aneurysm location and size, severity of subarachnoid bleeding, and clinical grade. Surgery-and coiling procedure-related mortality was similar in both groups, and there was no difference in the shortterm clinical outcome. One-year clinical and neuropsychological outcomes were comparable (10,11).
The International Subarachnoid Aneurysm Trial (ISAT) is a multicenter, randomized clinical trial comparing a policy of neurosurgical clipping with a policy of endovascular treatment with detachable platinum coils in patients with ruptured intracranial aneurysms considered suitable for either treatment (12). In all, 9278 patients were evaluated for eligibility, and finally clinical equipoise was observed in 2143 patients who were enrolled in the study and randomly assigned to endovascular treatment (n = 1073) or neurosurgical clipping (n = 1070). Almost all (97.3%) lesions were located in the anterior circulation, 50.5% in the anterior cerebral artery (ACA), 32.5% in the internal cerebral artery (ICA), and 14.1% in the middle cerebral artery (MCA), with only 2.7% of lesions in the posterior circulation. The great majority of the aneurysms were 10 mm or smaller in size. At 1 yr, 23.7% of patients allocated to endovascular treatment were dead or dependent compared with 30.6% in the surgical group. The relative risk of dependence or death was reduced by 22.6% in patients treated with endovascular coiling, with an absolute risk reduction of 6.9%. Trial recruitment was stopped by the steering committee after a planned interim analysis, but followup will continue.
In a retrospective observational study, Johnston et al. (13) compared the risks of endovascular and surgical treatment in 130 patients with unruptured cerebral aneurysms, who were considered candidates for either procedure on blinded review, and overall anticipated procedure risk was rated as identical. Surgery was found to be associated with greater rates of early and persistent disability, more procedure-related major complications, and longer delays in return of function. Length of stay was longer, and hospital charges were greater for the surgical group.
A permanent complication rate of 7% was shown on metaanalysis of 1383 patients with intracranial aneurysms, treated with endovascular GDC embolization (9).
In a recent review on surgery of unruptured aneurysms in 2460 patients, the morbidity was 11% and mortality 3% (14) . The International Study of Unruptured Intracranial Aneurysms (ISUIA) showed an unexpectedly high rate of neurological deficits, cognitive impairement, and mortality after surgical clip-
